Accepted for/Published in: JMIR Research Protocols
Date Submitted: Nov 11, 2019
Date Accepted: Sep 17, 2020
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Developing a blockchain-based supply chain system for advanced therapies: study protocol
ABSTRACT
Background:
Advanced therapies, including cell and gene therapies, have shown therapeutic promise in curing life-threatening diseases such as leukaemia and lymphoma. However, they can be complicated and expensive to deliver due to their sensitivity to environment, troublesome tissue, cell, or genetic material sourcing and complicated regulatory requirements
Objective:
This study aims to create a novel connected supply chain logistics and manufacturing management platform based on blockchain, with cell and gene therapy as a use case. Objectives are to define the requirements and perform feasibility evaluations on the use of blockchain for standardized manufacturing and establishment of chain of custody for the needle-to-needle delivery of autologous cell and gene therapies. A way of lowering overall regulatory compliance costs for running a network of facilities operating similar or parallel processes will be evaluated by lower monitoring costs through publishing zero-knowledge proofs and product release by exception.
Methods:
The study will use blockchain technologies to digitally connect and integrate supply chain with manufacturing to address the security, scheduling and communication issues between advanced therapy treatment centres and manufacturing facilities in order to realise a transparent, secure, automated and cost-effective solution to the delivery of these life-saving therapies. An agile software development methodology will be used to develop, implement, and evaluate the system. The system will adhere to EU and US Good Manufacturing Practices and regulatory requirements.
Results:
This is a proposed protocol and results pending.
Conclusions:
The successful implementation of the integrated blockchain solution to supply chain and manufacturing of advanced therapies can push the industry standards towards a safer and more secure therapy delivery process.
Citation
